
RBC Capital downgraded Vitalhub (VHIBF) to Sector Perform from Outperform with a price target of C$8, down from C$11. The company’s organic growth could continue to slow in the near
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| VHIBF | Vitalhub | 4.61 | -1.95 | -29.76% |
| Name | Price | % Change | |
|---|---|---|---|
| $4.61 | -29.76% |

RBC Capital downgraded Vitalhub (VHIBF) to Sector Perform from Outperform with a price target of C$8, down from C$11. The company’s organic growth could continue to slow in the near

Vitalhub Corp. (($TSE:VHI)) has held its Q3 earnings call. Read on for the main highlights of the call. VitalHub’s earnings call carried a broadly positive tone, with management highlighting 14%

Vitalhub Corp. (VHI) is scheduled to report 3rd quarter earnings on 11/12/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Vitalhub Corp. to post earnings of C$0.07

Vitalhub Corp. (($TSE:VHI)) has held its Q2 earnings call. Read on for the main highlights of the call. Vitalhub Corp.’s latest earnings call struck a notably upbeat tone, underscored by

TD Cowen analyst maintained a Buy rating on Vitalhub yesterday and set a price target of C$13.00. analyst has given his Buy rating due to a combination of factors tied

Raymond James analyst Michael W. Freeman has maintained their bullish stance on VHI stock, giving a Buy rating on August 7. Michael W. Freeman has given his Buy rating due

An update from Vitalhub ( ($TSE:VHI) ) is now available. VitalHub reported a robust second quarter of 2026, crossing the $100 million mark in annual recurring revenue and posting 33%

, an analyst from TD Cowen, maintained the Buy rating on Vitalhub. The associated price target is C$13.00. analyst has given his Buy rating due to a combination of factors

Vitalhub ( ($TSE:VHI) ) has provided an announcement. VitalHub’s Novari Health unit has signed a multi-year agreement with the province of Ontario to roll out its central intake referral technology

Stifel lowered the firm’s price target on Vitalhub (VHIBF) to C$11 from C$13.50 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 31, 2027TBA | $310.99M | $0.05 | $23.57M | 1.48 | 40.16 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.